Spire Healthcare Group (LON:SPI) Price Target Raised to GBX 300

Spire Healthcare Group (LON:SPI - Get Free Report) had its price target lifted by equities researchers at Berenberg Bank from GBX 286 ($3.56) to GBX 300 ($3.73) in a research note issued on Wednesday, MarketBeat.com reports. The firm currently has a "buy" rating on the stock. Berenberg Bank's target price would indicate a potential upside of 20.97% from the stock's current price.

Separately, JPMorgan Chase & Co. restated an "overweight" rating and set a GBX 295 ($3.67) target price on shares of Spire Healthcare Group in a report on Monday, February 26th.

Spire Healthcare Group Price Performance

SPI stock traded up GBX 9.50 ($0.12) during trading on Wednesday, hitting GBX 248 ($3.09). The company had a trading volume of 2,573,226 shares, compared to its average volume of 454,168. The company has a fifty day moving average price of GBX 237.57 and a two-hundred day moving average price of GBX 228.97. Spire Healthcare Group has a fifty-two week low of GBX 204 ($2.54) and a fifty-two week high of GBX 321.71 ($4.00). The company has a market cap of £1.00 billion, a P/E ratio of 3,542.86, a P/E/G ratio of 1.06 and a beta of 0.99. The company has a current ratio of 0.69, a quick ratio of 0.74 and a debt-to-equity ratio of 170.37.

Spire Healthcare Group Company Profile

Spire Healthcare Group plc, together with its subsidiaries, owns and operates private hospitals and clinics. It offers various treatments in the areas of allergy and infectious diseases, blood tests, bones and joints, bowel treatments, breast screening and surgery, cancer investigations and treatments, cosmetic surgery, cyst removal, and dental surgery, as well as ear, nose, and throat treatments.